Medtronic fully exits diabetes.
The parent company’s support has an expiration date. Is your brand ready to stand on its own?
Medtronic is fully separating its diabetes business, MiniMed, into an independent company. And there’s a brand lesson hiding inside the corporate finance news which nicely build on last week’s MedTech’s Great Unbundling post.
Here’s how it played out. MiniMed went public in March, with Medtronic keeping about 90%. Medtronic then let its own shareholders swap Medtronic shares for MiniMed shares. They tendered far more than Medtronic could accept, so Medtronic is handing over its entire remaining stake.
Finance and Legal are running this. But marketers should be paying attention, too.
Two things stand out:
First, carve-outs don’t all look alike. A sale to private equity and an IPO followed by a split-off are different routes, but both end with a business that has to stand on its own.
Second, there’s a clock. Medtronic’s transition services agreement with MiniMed is generally not expected to run past 24 months after the IPO. Whatever the parent quietly supplied behind the scenes, MiniMed eventually has to supply itself. And a newly public company has two audiences listening: customers and clinicians, and investors.
That includes credibility. Some of it belongs to the product. Some of it may have been borrowed from the parent.
So here’s what we recommend for a brand going through this:
• List what customers assume the parent provides: support, training, service, reputation, etc.
• For each one, decide whether to rebuild it, replace it, or stop promising it.
• Put dates on those decisions, working back from the end of the transition period.